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                                      Müllerian inhibiting substance (MIS) is a member of the trans-
forming growth factor      family of growth and differentiation 
factors and is primarily known for its role in regulating in utero 
sexual differentiation of boys (  1  ). In girls, MIS is secreted by the 
ovaries beginning during the prepubertal period (  2  ). Serum 
levels remain elevated during women’s reproductive years but 
decline gradually when ovaries age, reaching undetectable levels 
at menopause (  2    –    4  ). MIS plays a key role in regulating the nor-
mal development of the breast. In particular, MIS stimulates 
apoptosis of breast ductal epithelium and, in vivo, inhibits pro-
liferation of mammary ducts (  5  ). MIS has been reported to have 
direct inhibitory effects on breast tumor growth. It has been 
shown to inhibit growth of breast cancer cell lines in vitro via 
inhibition of cell cycle progression and induction of apoptosis 
(  6  ). MIS also has been reported to suppress mammary tumor 
growth in mouse models (  7  ). Thus, MIS potentially could 
decrease breast cancer risk via effects on breast morphology or 
via direct effects on tumor growth. Alternatively, MIS is a 
marker of ovarian reserves such that serum levels decline with 
ovarian aging and the approach of menopause (  3  ,  4  ). In premen-
opausal women at a median age of 40 years, a decline in serum 
MIS levels has been shown to be inversely associated with 
occurrence of the menopausal transition during the next 4 years 
(  8  ). Thus, higher MIS levels in older premenopausal women 
may indicate an older age at menopause and, thereby, be asso-
ciated with increased breast cancer risk. To clarify the associa-
tion of serum MIS concentration with breast cancer risk, we 
conducted a prospective case  –  control study nested in the 
Columbia, Missouri (MO) Serum Bank. 
    Affiliations of authors:   Fox Chase Cancer Center, Philadelphia, PA (JFD, 
BLE, CMS, CSS, AKG); Department of Obstetrics and Gynecology and 
Department of Preventive Medicine, University of Southern California 
Keck School of Medicine, Los Angeles, CA (FZS); Information Management 
Services, Rockville, MD (LLK); Division of Cancer Epidemiology and 
Genetics, National Cancer Institute, Rockville, MD (LAB)  .     
    Correspondence to:   Joanne F. Dorgan, PhD, MPH, Fox Chase Cancer Center, 
333 Cottman Ave, Philadelphia, PA 19111 (e-mail:   joanne.dorgan@fccc.edu  ).   
      See   “Funding” and “Notes” following “References.”   
      DOI:   10.1093/jnci/djp331   
    © The Author 2009. Published by Oxford University Press. 
This is an Open Access article distributed under the terms of the Creative Com-
mons Attribution Non-Commercial License (http://creativecommons.org/licenses/
by-nc/2.5/uk/) which permits unrestricted non-commercial use, distribution, and 
reproduction in any medium, provided the original work is properly cited.   
    Advance Access publication on October 9, 2009.   
          Prospective Case  –  Control Study of Serum Müllerian 
Inhibiting Substance and Breast Cancer Risk   
        Joanne F.           Dorgan        ,           Frank Z.           Stanczyk        ,           Brian L.           Egleston        ,           Lisa L.           Kahle        ,           Christiana M.           Shaw        ,           Cynthia 
S.           Spittle        ,           Andrew K.           Godwin        ,           Louise A.           Brinton                                     
     Background     Müllerian inhibiting substance (MIS) is a member of the transforming growth factor      family of growth 
and differentiation factors that inhibits elongation and branching of mammary ducts and has been shown 
to inhibit mammary tumor growth in vitro and in animal models. The objective of this study was to deter-
mine whether serum MIS levels are associated with breast cancer risk.   
     Methods     We conducted a prospective case  –  control study of 309 participants who were registered in the Columbia, 
Missouri Serum Bank. Each of 105 in situ or invasive breast cancer case patients with prediagnostic serum 
collected before menopause was matched to two control subjects by age, date, menstrual cycle day, and 
time of day of blood collection. MIS was measured in serum by using an enzyme-linked immunosorbent 
assay, and estradiol and testosterone concentrations were quantified by using specific radioimmunoassays. 
Data were analyzed using conditional logistic regression. All tests of statistical significance were two-sided.   
     Results     The relative odds ratio of breast cancer for women in increasing MIS quartiles were 1, 2.8 (95% confidence 
interval [CI] = 1.0 to 7.4), 5.9 (95% CI = 2.4 to 14.6), and 9.8 (95% CI = 3.3 to 28.9,   P    trend   < .001). The association 
of MIS with breast cancer was weaker in women who were not taking oral contraceptives at the time of blood 
collection, but adjustment for estradiol and testosterone levels did not materially alter results for these women. 
The association of MIS with breast cancer did not vary by age at blood collection but was stronger among 
women who were diagnosed with breast cancer at an older age than among those who were diagnosed at a 
younger age.   
     Conclusion     MIS may be a novel biomarker of increased breast cancer risk. Additional research including confirmatory 
epidemiological studies and mechanistic studies is needed.   
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    CONTEXT AND CAVEATS 
    Prior knowledge 
  Müllerian inhibiting substance (MIS) inhibits mammary tumor 
growth in vitro and in mouse models of breast cancer.   
    Study design 
  Prospective case  –  control study to determine whether MIS serum 
concentrations from blood samples that were collected before 
diagnosis are associated with breast cancer risk.   
    Contributions 
  Increasing MIS serum concentrations were associated with increased 
breast cancer risk in this population. Adjustment for estrogen and 
testosterone levels did not change the results. The association did 
not vary with age at blood collection but was stronger among 
women who were diagnosed with breast cancer at an older age.   
    Implications 
  Increased serum concentrations of MIS may be associated with 
increased breast cancer risk.   
    Limitations 
  The association of increased serum MIS concentrations and 
increased risk of breast cancer is in contrast to previous findings in 
vitro and in animal models and what is known about the mecha-
nisms of MIS on breast physiology. The patients in the population 
less frequently used oral contraceptives than the control subjects, 
which contrasts with previous data, and could indicate that the con-
trol population was not representative of the general population. 
    From the Editors       
    
    Subjects and Methods 
  The Columbia, MO Serum Bank initially was established in 1977 
as part of the National Cancer Institute’s Biological Markers 
Project to identify serum markers for breast cancer. Participants 
were volunteers identified primarily through the Breast Cancer 
Detection Demonstration Project at the University of Missouri 
Hospital and the Ellis Fischel Cancer Center in Columbia. A total 
of 6915 women who initially were free of cancer, other than non-
melanoma skin cancer, donated blood to the bank on one or more 
occasions between December 1977 and June 1989. All women gave 
written informed consent before donating serum to the serum 
bank, and the Fox Chase Cancer Center Institutional Review 
Board approved the research reported herein. 
  Serum specimens were collected and clinical data, including 
age, height, weight, menstrual and reproductive histories, smoking, 
hormone replacement and oral contraceptive use, and family his-
tory of breast cancer, were obtained by self-report or medical 
record review. Approximately 30 mL of blood were collected from 
each woman using standard procedures. Blood was allowed to 
stand at room temperature for at least one-half hour or until it was 
thoroughly clotted and then refrigerated. Within 2 hours of col-
lection, blood was centrifuged and serum was separated and ali-
quoted into 1.1-mL sterile glass vials. Vials were labeled, sealed 
with rubber stoppers, and stored at     70°C. 
  Follow-up of women who donated blood to the Columbia, MO 
Serum Bank was conducted in two phases. Initial follow-up contin-
ued for up to 12 years until December 1989. A questionnaire was 
mailed to participants annually to ascertain information on interim 
cancer diagnoses. Women who indicated that they had a breast 
biopsy or breast cancer were sent a consent form for permission to 
obtain medical records including pathology reports. For cancers at 
sites other than the breast, date of diagnosis was ascertained. An 
extended follow-up of Columbia, MO Serum Bank participants was 
conducted by the National Cancer Institute in 1999  –  2004. Cancer 
diagnoses were ascertained via self-report and by searching the 
Missouri Cancer Registry, Breast Cancer Detection Demonstration 
Project Cohort ﬁ  les, and National Death Index Plus. Of the 6720 
women included in the extended follow-up because they had one or 
more vials of serum remaining, 6131 (91%) were located as either 
alive or dead, 589 (9%) were not able to be located, 59 (<1%) 
refused to participate, and 49 (<1%) were too ill to participate. A 
total of 1751 women (25%) were identiﬁ  ed as deceased with conﬁ  r-
mation of causes of death provided via National Death Index. 
  Case patients for the current study included women in the 
Columbia, MO Serum Bank who were free of cancer other than 
nonmelanoma skin cancer at the time they donated blood while 
they were premenopausal and who subsequently were diagnosed 
with in situ or invasive breast cancer that was conﬁ  rmed by medical 
records, the Missouri Cancer Registry, or the National Death 
Index. Initially, potential case patients were selected if less than 
1 year had elapsed since their last menses or if they were younger 
than 50 years at blood collection and were missing data on (ie, had 
not recorded) the date of their last menses. (Fifty years is the me-
dian age at menopause for naturally menopausal women in the 
Columbia, MO Serum Bank.) For each of 122 potential case 
patients that were identiﬁ  ed, two potential control subjects were 
randomly selected who met these same criteria but remained free 
of cancer. They were matched to the case patient by age (±2 years), 
date (±1 year), menstrual cycle day (±2 days; if the potential case 
patient was missing data on the date of her last menses, a potential 
control subject with missing data on the date of her last menses was 
selected), and time of day (±2 hours) of blood collection. Matching 
criteria were relaxed by age for 14 potential control subjects (me-
dian = 4.4 years), by date for 18 potential control subjects (median = 
2.2 years), by cycle day for 20 potential control subjects (median = 9 
days), and by time for nine potential control subjects (median = 3 
hours). Final determination of menopausal status for potential par-
ticipants who were missing data on the date of their last menses was 
based on age at blood collection, use of exogenous estrogens, and 
serum follicle stimulating hormone (FSH) and estradiol concentra-
tions. Because 44 years is the 10th percentile of age at menopause 
in naturally menopausal women in the Columbia, MO Serum 
Bank, women who were aged 44 years or younger at blood collec-
tion and missing data on the date of their last menses were pre-
sumed to be premenopausal. For women who were aged 45 years 
or older and missing data on the date of their last menses, serum 
FSH and estradiol were measured. Those with serum FSH con-
centrations greater than 25 mIU/mL and estradiol concentrations 
less than 25 pg/mL were considered to be postmenopausal and 
excluded from analysis. This is the standard biochemical deﬁ  nition 
of menopause used by the laboratory where the assays were per-
formed. We also excluded women who were aged 45 years 
or older, missing data on the date of their last menses, and using 
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their menopausal status could not be determined. After exclusion 
of postmenopausal women and women with indeterminate 
menopausal status, 105 case patients and 204 matched control 
subjects remained and were included in analyses. 
  All laboratory analyses were performed at the Reproductive 
Endocrine Research Laboratory, University of Southern California 
Keck School of Medicine. Serum from each case patient and her 
matched control subjects was grouped together and matched sets 
were randomly organized within batches. The laboratory was 
blinded to which samples were from case patients and which were 
from control subjects. MIS was quantiﬁ  ed using a commercially 
available enzyme-linked immunosorbent assay kit that uses a mono-
clonal antibody against MIS (Diagnostics Systems, Webster, TX). 
Estradiol and testosterone in serum could potentially confound 
associations of MIS with breast cancer risk. Thus, estradiol and 
testosterone were quantiﬁ   ed by speciﬁ   c radioimmunoassays fol-
lowing extraction and Celite column partition chromatography as 
described previously ( 9  ,  10  ). Sex hormone –  binding globulin (SHBG) 
was measured by a chemiluminescent immunoassay on the Immulite 
analyzer (Siemens Medical Solutions, Los Angeles, CA) to allow 
calculation of bioavailable (free plus albumin-bound) estradiol and 
testosterone (  11    –    13  ). FSH was similarly measured on the Immulite 
analyzer. The average coefﬁ  cient of variation for MIS was 8.0% 
and its limit of detection was 0.06 ng/mL. As for other serum bio-
markers, the average coefﬁ  cients of variation were 8.5% for estra-
diol, 11.2% for testosterone, 7.0% for SHBG, and 6.9% for FSH. 
    Statistical Analysis 
  The association of serum MIS with breast cancer risk for matched 
sets was evaluated using conditional logistic regression. Women 
were stratified into quartiles of MIS, and a set of categorical 
(dummy) variables was included in the models. Models were fit 
using quartile ranks entered as a linear term to test for trend 
because the MIS values were extremely skewed. For women with 
MIS levels below the assay limit of detection, the value was 
imputed using 0.03 ng/mL, which is the midpoint between 0 and 
the assay limit of detection. Univariate associations of individual 
characteristics including age at blood collection (continuous), 
height (continuous), body mass index (BMI) (continuous), age at 
menarche (continuous), age at first pregnancy (continuous), 
number of full-term pregnancies (continuous), use of exogenous 
estrogens (referred to as oral contraceptives in the remainder of 
the article; yes or no), smoking (never, former, or current), history 
of breast cancer in a first-degree relative (yes or no), and days since 
last menses when blood was collected (categorized to approximate 
menstrual cycle phase [follicular: days 0  –  8, midcycle: days 9  –  14, 
luteal: days 15  –  33, long cycles: days 34+]) with breast cancer were 
evaluated using conditional logistic regression to retain the match-
ing. Associations of these characteristics with serum MIS concen-
tration in control subjects were evaluated by estimating medians 
and testing statistical significance of differences using the Wilcoxon 
rank sum or Kruskal  –  Wallis test for categorical variables and by 
Spearman correlations for continuous variables. Analyses to eval-
uate associations of total and bioavailable estradiol and testoster-
one concentrations with serum MIS and breast cancer risk were 
restricted to participants not using oral contraceptives. For two 
participants with estradiol concentrations below the assay limit of 
detection, the value was imputed to be 1.5 pg/mL, which is the 
midpoint between 0 and the limit of detection. Associations of 
total and bioavailable estradiol and testosterone with MIS concen-
tration in control subjects were evaluated using Spearman correla-
tions. Median concentrations for each hormone in case patients 
and control subjects were calculated and compared by testing the 
statistical significance of the trend of quartile ranks entered as a 
linear term in conditional logistic regression models. Characteristics 
associated with breast cancer risk and serum MIS concentration at 
  P   less than .10 in univariate analyses were deemed potential con-
founders. A forward stepwise approach was used to evaluate con-
founding; variables were considered to be confounders if they 
changed the estimate of the odds ratio (OR) for the highest quar-
tile of MIS by 10% or more. In an age-stratified analysis, women 
were classified into tertiles of MIS because of small numbers in 
some cells with finer gradation. Effect modification was assessed 
by testing the statistical significance of cross-product terms in 
models. All tests of statistical significance were two-sided and a 
cutoff of   P   less than .05 was used to determine statistical signifi-
cance. All analyses were performed using SAS 9.2 (Cary, NC).     
    Results 
  Participant characteristics are summarized in   Table 1  . All women 
were premenopausal at the time of blood collection. One case 
patient and one control subject were African American, and the 
remainder were white. Case patients  ’   and control subjects  ’   ages av-
eraged 44.6 years (range = 31.4  –  56.1 years) and 44.7 years (range = 
33.3  –  54.7 years), respectively. Case patients did not differ from 
control subjects in terms of anthropometric or reproductive charac-
teristics. Fewer case patients used oral contraceptives compared 
with control subjects (4.8% vs 12.2%;   P   = .05), and more case 
patients had a history of breast cancer in a first-degree relative com-
pared with control subjects (18.1% vs 7.4%;   P   = .007). Data on date 
of last menses were missing for 15.2% of case patients and 13.2% of 
control subjects, and 8.6% of case patients and 6.9% of control 
subjects had blood collected 34 days or more after their last menses. 
The median number of days from last menses at blood collection for 
these participants was 51 days (range = 35  –  81 days). Case patients  ’   
mean (±SD) age at breast cancer diagnosis was 58.7 ± 8.3 years 
(range = 37.7  –  74.0 years). The mean (±SD) time from blood collec-
tion to diagnosis was 14.1 ± 6.6 years.         
  Correlations of serum MIS concentration with individual char-
acteristics of control women are shown in   Table 2  . MIS concen-
tration was statistically signiﬁ  cantly inversely correlated with age 
at blood collection (Spearman   r   =     0.64;   P   < .001). MIS was not 
correlated with the anthropometric and reproductive characteris-
tics that were examined, including number of pregnancies as a 
continuous variable. However, nulliparous women had lower MIS 
levels compared with parous women (  P   = .04); their median con-
centrations were 0.03 ng/mL (5  –  95 percentiles = 0.03  –  1.6 ng/mL) 
and 0.10 ng/mL (5  –  95 percentiles = 0.03  –  2.4 ng/mL), respec-
tively. MIS levels did not differ by family history of breast cancer 
(in a ﬁ  rst-degree relative) or by smoking status (data not shown). 
MIS levels also did not differ by the number of days since the start 
of the women’s last menses when blood was collected during the 
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phases of the cycle. The median concentration was 0.2 ng/mL 
(5  –  95 percentiles = 0.03  –  2.5 ng/mL). In contrast, all control sub-
jects whose blood was collected at 34 days or more after last 
menses had MIS levels below the assay limit of detection (imputed 
value = 0.03 ng/mL), which was statistically signiﬁ  cantly lower 
than for those whose blood was collected within 33 days of last 
menses (  P   < .001). The median MIS concentration for control 
subjects who were missing data on the date of last menses was 0.03 
ng/mL (5  –  95 percentiles = 0.03  –  1.1 ng/mL), which was not statis-
tically signiﬁ  cantly different from the median MIS concentration 
for subjects with a known date of last menses overall or that for 
control subjects whose blood was collected within 33 days of last 
menses. Control subjects using oral contraceptives at the time 
of blood collection had statistically signiﬁ  cantly lower MIS con-
centrations compared with those not using oral contraceptives 
(  P   = .006); median concentrations were 0.03 ng/mL (5  –  95 percen-
tiles = 0.03  –  0.5 ng/mL) and 0.1 ng/mL (5  –  95 percentiles = 0.03  –  2.5 
ng/mL), respectively.       
  As shown in   Figure 1  , case patients had higher MIS concentra-
tions than control subjects. In analysis that included all participants, 
case patients  ’   and control subjects  ’   median MIS values were 0.4 ng/
mL and 0.1 ng/mL, respectively (  P   < .001). Similar results were 
obtained when the analysis was restricted to matched sets in which 
the case patient and at least one control subject were not using oral 
contraceptives (  Table 3  ). Among participants who did not use oral 
contraceptives, total and bioavailable estradiol concentrations did 
not differ between the groups (  Table 3  ). However, case patients had 
statistically signiﬁ  cantly higher total testosterone and bioavailable 
testosterone concentrations than control subjects.                 
  Serum MIS concentration was strongly and statistically signiﬁ  -
cantly positively associated with risk of developing breast cancer 
(  P    trend   < .001;   Table 4  ). Risk increased monotonically with in-
creasing MIS concentration; the relative odds ratios for increasing 
quartiles of MIS were 1.0, 2.8 (95% conﬁ  dence interval [CI] = 1.0 
to 7.4), 5.9 (95% CI = 2.4 to 14.6), and 9.8 (95% CI = 3.3 to 28.9). 
Adjustment for potential confounders and BMI did not substan-
tially change risk estimates (BMI-adjusted models, increasing MIS 
quartiles, OR = 1, OR = 2.6, 95% CI = 1.0 to 7.2; OR = 5.6, 95% 
CI = 2.3 to 13.9; and OR = 9.9, 95% CI = 3.3 to 29.2;   P    trend   < .001). 
There also was no evidence of effect modiﬁ  cation of the MIS 
  Table 1    .       Participant characteristics at blood collection  *     
    Characteristic Case patients (n = 105) Control subjects (n = 204)    
    Continuous variables Mean ± SD   P      †     
         Age, y 44.6 ± 4.7 44.7 ± 4.4 .10 
         Height, cm 163.3 ± 6.0 164.2 ± 5.9 .26 
         BMI, kg/m 
2  25.9 ± 5.5 25.0 ± 4.7 .13 
         Menarche, y 12.4 ± 1.3 12.7 ± 1.4 .12 
         Age at first pregnancy, y    ‡    22.3 ± 4.1 22.0 ± 3.9 .58 
         No. of full-term pregnancies 2.7 ± 1.6 2.8 ± 1.6 .62 
  Categorical variables Frequency, No. (%)   P    §   
         Nulliparous 9 (8.6%) 14 (6.9%) .71 
         Oral contraceptive use    ||    5 (4.8%) 25 (12.2%) .05 
         Smoking status     .81 
                Never 67 (63.8%) 127 (62.2%)  
                Former 19 (18.1%) 34 (16.7%)  
                Current 19 (18.1%) 43 (21.1%)  
         History of breast cancer in first-degree relative 19 (18.1%) 15 (7.4%) .007 
         Menstrual cycle day at blood collection     .29 
                Days 0  –  8 23 (21.9%) 47 (23.0%)  
                Days 9  –  14 19 (18.1%) 36 (17.6%)  
                Days 15  –  33 38 (36.2%) 80 (39.2%)  
                Days   ≥  34 9 (8.6%) 14 (6.9%)  
                Unknown 16 (15.2%) 27 (13.2%)    
    *     Participants are case patients and control subjects in the prospective case  –  control study of serum Müllerian inhibiting substance and breast cancer risk nested in 
the Columbia, Missouri Serum Bank. BMI = body mass index.   
      †         P   values (two-sided) were calculated by using conditional logistic regression using a Wald test.   
      ‡       Includes 96 parous case patients and 190 parous control subjects.   
    §       P   values (two-sided) were calculated by using conditional logistic regression using a Wald test for categorical variables with two categories or a likelihood ratio 
test for categorical variables with more than two categories.   
      ||       Oral contraceptive use at time of blood collection.     
  Table 2    .       Correlations of serum Müllerian inhibiting substance 
concentration with characteristics of control subjects (n = 204)  *     
    Characteristic Spearman correlation   P      †       
    Age, y     .64 <.001 
  Height, cm .01 .87 
  BMI, kg/m  2 .07 .33 
  Menarche, y .07 .34 
  Age at first pregnancy, y    ‡       .05 .47 
  No. of full-term pregnancies .08 .28   
    *     Control subjects are from the prospective case  –  control study of serum 
Müllerian inhibiting substance and breast cancer risk nested in the Columbia, 
Missouri Serum Bank. All variables are continuous. BMI = body mass index.   
      †         P   values (two-sided) were calculated by using a   t  -statistic transformation to 
test correlation = 0.   
      ‡       Includes 190 parous control subjects.     jnci.oxfordjournals.org    JNCI | Articles 1505
breast cancer association by BMI (  P    interaction   = .43 between BMI and 
MIS quartile rank when included in model).         
  The association of serum MIS with breast cancer was weaker 
but remained statistically signiﬁ  cant in women not using oral con-
traceptives at the time of blood collection (  P    trend   < .001;   Table 4  ). 
In an analysis restricted to 98 matched sets in which the case 
patient and at least one control subject were not using oral contra-
ceptives, the odds ratios for increasing quartiles of MIS were 1.0, 
2.3 (95% CI = 0.9 to 6.2), 4.2 (95% CI = 1.6 to 10.9), and 7.3 (95% 
CI = 2.3 to 23.6). Because only ﬁ  ve case patients used oral contra-
ceptives at the time of blood collection, associations of MIS with 
breast cancer among oral contraceptive users were not reported. 
  Of the 105 women diagnosed with breast cancer, 12 had in situ 
cancers and 93 had invasive cancers. Results of an analysis restricted 
to invasive breast cancer were similar to those for in situ and invasive 
cancers combined that is shown above (for all invasive breast cancer, 
increasing MIS quartiles of MIS, OR = 1, OR = 3.0, 95% CI = 1.1 to 
8.5; OR = 5.8, 95% CI = 2.2 to 14.9; and OR = 9.1, 95% CI = 3.0 to 
28.1;   P    trend   < .001). The association was weaker in the 86 matched sets 
of women who did not use oral contraceptives at the time of blood 
collection (OR = 1; OR = 2.5, 95% CI = 0.9 to 7.1; OR = 4.0, 95% 
CI = 1.5 to 10.7; and OR = 6.6, 95% CI = 2.0 to 22.1;   P    trend   = .001). 
  Among control subjects not using oral contraceptives, serum MIS 
concentrations were not correlated with total estradiol (Spearman 
  r   = .12;   P   = .10) or total testosterone (Spearman   r   = .14;   P   = .07) 
concentrations. MIS concentrations, however, were correlated with 
concentrations of the bioavailable fractions of these hormones (for 
non  –  SHBG-bound estradiol, Spearman   r   = .16,   P   = .03; for non  –
  SHBG-bound testosterone, Spearman   r   = .21,   P   = .005). 
  Adjustment for total and non  –  SHBG-bound estradiol and tes-
tosterone did not substantially change risk estimates for MIS 
among women who were not using oral contraceptives at the time 
of blood collection (highest vs lowest MIS quartile, adjusted for 
total estradiol, OR = 6.9, 95% CI = 2.1 to 22.6; adjusted for non  –
  SHBG-bound estradiol, OR = 7.4, 95% CI = 2.3 to 24.0; adjusted 
for total testosterone, OR = 8.1, 95% CI = 2.4 to 27.9; adjusted for 
non  –  SHBG-bound testosterone, OR = 6.9, 95% CI = 2.1 to 22.6). 
The association of MIS with breast cancer risk remained statisti-
cally signiﬁ  cant after adjustment for each of these hormones (  P    trend   < 
.002). Tests for interaction between MIS and total or bioavailable 
estradiol and testosterone in relationship to breast cancer risk were 
not statistically signiﬁ  cant. 
  To explore the association of MIS with breast cancer by age 
at blood collection, we conducted analyses stratiﬁ  ed by age less 
than 45 years or 45 years and older at time of blood collection 
(  Table 5  ). In 100 matched sets, the case patient and at least one 
control subject were either less than 45 years old (56 sets) or 45 
years and older (44 sets) at blood collection. MIS was positively 
associated with breast cancer risk in both age strata. The associ-
ation was similar among younger women (highest vs lowest MIS 
tertile, OR = 7.5, 95% CI = 1.9 to 29.8;   P    trend   = .002) and among 
older women (highest vs lowest MIS tertile, OR = 6.9, 95% CI = 
1.1 to 42.0;   P    trend   = .01). The test for interaction between MIS and 
age at blood collection was not statistically signiﬁ  cant. (Lower 
risk estimates from this stratiﬁ   ed analysis compared with the 
unstratiﬁ  ed analysis shown above is a result of using tertiles vs 
quartiles of MIS.)         
  Because MIS varies only slightly over the menstrual cycle (  14  ), 
we included women with missing data on the date of their last men-
ses at blood collection if they met our criteria for being premeno-
pausal. Because 44 years was the 10th percentile of age at natural 
menopause in the cohort, women who were 44 years old or younger 
at blood collection were eligible even though some with missing 
data on the date of their last menses could have been postmeno-
pausal. In an analysis that excluded these women, the association 
of MIS with breast cancer was stronger (highest vs lowest MIS 
  Table 3    .       Median (5  –  95th percentiles) hormone concentrations in case patients and control subjects not using oral contraceptives  *     
    Case patients (n = 98) Control subjects (n = 169)
  P      †       Median 5  –  95th percentiles Median 5  –  95th percentiles   
    Müllerian inhibiting substance, ng/mL 0.30 0.03  –  3.4 0.10 0.03  –  2.5 <.001 
  Estradiol, pg/mL 92.5 23.0  –  277.0 98.0 12.0  –  248.0 .97 
  Bioavailable estradiol, pg/mL 56.5 12.2  –  153.2 54.8 8.6  –  146.1 .84 
  Testosterone, ng/dL 27.5 16.0  –  49.6 25.7 13.0  –  44.3 .01 
  Bioavailable testosterone, ng/dL 11.7 5.7  –  23.5 10.2 4.9  –  19.0 .004 
  SHBG, nmol/L 57.5 27.3  –  114.0 60.7 26.1  –  117.0 .24   
    *     Case patients and control subjects from matched sets where the case patient and at least one control subject were not using oral contraceptives at blood 
collection in the prospective case  –  control study of serum Müllerian inhibiting substance and breast cancer risk nested in the Columbia, Missouri Serum Bank. 
All variables are continuous. SHBG    =    sex hormone  –  binding globulin.   
      †         P   values (two-sided) were calculated by using conditional logistic regression with quartile ranks entered as a linear term to test for trend using a Wald test.     
   
    Figure 1    .        Serum Müllerian inhibiting substance (MIS) by age in case 
patients and control subjects. Natural logarithm of serum MIS level 
plotted by age in case patients (  blue circles  ) and control subjects (  orange   
  triangles  ) and smoothed lines ﬁ  t with a kernel smoother for case patients 
(  blue solid line  ) and control subjects (  orange     dashed line  ).         1506   Articles | JNCI  Vol. 101, Issue 21  |  November 4, 2009
quartile, OR = 13.6, 95% CI = 3.8 to 48.2;   P   < .001). Results were 
similar in an analysis that excluded all women with missing data on 
date of their last menses or for women whose blood was collected 
more than 33 days after their last menses (highest vs lowest MIS 
quartile, OR = 12.5, 95% CI = 3.5 to 44.3;   P    trend   < .001). 
  Because we did not have data on eventual age at menopause, we 
could not perform an analysis stratiﬁ  ed by menopausal status at 
diagnosis. As a proxy, we conducted an analysis stratiﬁ  ed by age at 
diagnosis (  Table 6  ). Thirty-two case patients were younger than 
55 years at breast cancer diagnosis. When we restricted the analysis 
to these case patients and their matched control subjects, serum 
MIS concentration remained positively associated with breast can-
cer (highest vs lowest MIS tertile, OR = 3.9, 95% CI = 0.9 to 16.3; 
  P    trend   = .03). In a similar analysis for the 73 matched sets in which 
the case patient was aged 55 years or older at diagnosis, the positive 
association of MIS with breast cancer risk was stronger (highest vs 
lowest MIS tertile, OR = 9.6, 95% CI = 2.8 to 33.3;   P    trend   < .001).         
  The time from blood collection to diagnosis ranged from 2 
months to 23 years. When we repeated analyses restricted to the 
68 case patients whose blood was collected at least 12 years before 
diagnosis and their matched control subjects, results were similar 
to those from analyses that included all case patients (shown in 
  Table 4  ) (highest vs lowest MIS quartile, OR = 9.0, 95% CI = 2.3 
to 35.5;   P    trend   = .001).   
    Discussion 
  To our knowledge, this is the first prospective study of premeno-
pausal serum MIS concentration and breast cancer risk. We 
observed a strong positive association of MIS concentration with 
breast cancer (highest quartile of MIS vs lowest quartile, OR = 9.8, 
95% CI = 3.3 to 28.9). The association was somewhat weaker in 
women who were not using oral contraceptives at the time of 
blood collection (highest MIS quartile vs lowest, OR = 7.3, 95% 
CI = 2.3 to 23.6). Adjustment for serum estradiol and testosterone 
concentrations in data from women who did not use oral contra-
ceptives did not materially alter the association of MIS with breast 
cancer. The association of MIS with breast cancer did not vary by 
age at blood collection but was stronger among women who were 
diagnosed with breast cancer at an older age than among those 
who were diagnosed at a younger age. These results suggest that 
MIS may be a novel biomarker of breast cancer risk. 
  Data from in vitro studies and animal models support a protec-
tive effect of MIS for breast cancer (  6  ,  7  ). However, in this ﬁ  rst 
study to evaluate the association of serum MIS with breast cancer 
risk in humans, we found little evidence for an inverse association 
between serum MIS concentration and breast cancer. By contrast, 
MIS concentration was statistically signiﬁ  cantly positively related 
to breast cancer risk. MIS acts by binding to its receptor (MISRII), 
  Table 4    .       Relative odds ratios (ORs) and confidence intervals (CIs) of breast cancer by serum Müllerian inhibiting substance (MIS) 
concentration   
    MIS, ng/mL
All participants  *  Excluding oral contraceptive users  *      †     
  No. of case patients/
No. of control subjects OR (95% CI)   P      ‡   
No. of case patients/
No. of control subjects OR (95% CI)   P      ‡       
       <.001     <.001 
  <0.06 28/90 1.0  28/70 1.0  
  0.1 10/20 2.8 (1.0 to 7.4)   10/16 2.3 (0.9 to 6.2)  
  0.2  –  0.8 35/51 5.9 (2.4 to 14.6)   31/45 4.2 (1.6 to 10.9)  
  0.9  –  8.0 32/43 9.8 (3.3 to 28.9)   29/38 7.3 (2.3 to 23.6)    
    *     Case patients and control subjects are from the prospective case  –  control study of serum MIS and breast cancer risk nested in the Columbia, Missouri Serum 
Bank. Case patients and control subjects were matched on age, date, hour, and days since last menses at blood collection. MIS cut points define quartiles of MIS 
estimated from all participants.   
      †       Includes only matched sets where the case patient and at least one control subject were not using oral contraceptives at blood collection.   
      ‡         P   values (two-sided) were calculated by using conditional logistic regression with quartile ranks entered as a linear term to test for trend using a Wald test.     
  Table 5    .       Relative odds ratios (ORs) and confidence Intervals (CIs) of breast cancer by serum Müllerian inhibiting substance (MIS) 
concentration stratified by age at blood collection   
    MIS, ng/mL
Age <45 y  *      †    Age   ≥  45 y  *      ‡     
  No. of case patients/
No. of control subjects OR (95% CI)   P    § 
No. of case patients/
No. of control subjects OR (95% CI)   P  §   
       .002     .01 
  <0.06 3/21 1.0  25/60 1.0  
  0.1  –  0.5 15/38 3.0 (0.8 to 11.5)   13/15 3.2 (1.1 to 9.4)  
  0.6  –  8.0 38/49 7.5 (1.9 to 29.8)   6/4 6.9 (1.1 to 42.0)    
    *     Case patients and control subjects are from the prospective case  –  control study of serum MIS and breast cancer risk nested in the Columbia, Missouri Serum 
Bank. Case patients and control subjects were matched on age, date, hour, and days since last menses at blood collection. MIS cut points define tertiles of MIS 
estimated from all participants.   
      †       Includes only matched sets where the case patient and at least one control subject were less than 45 years old at blood collection.   
      ‡       Includes only matched sets where the case patient and at least one control subject were 45 years or older at blood collection.   
    §       P   values (two-sided) were calculated by using conditional logistic regression with tertile ranks entered as a linear term to test for trend using a Wald test.     jnci.oxfordjournals.org    JNCI | Articles 1507
and MISRII mRNA is expressed by normal breast epithelial cells, 
ﬁ  broadenomas, and ductal carcinomas (  6  ). Thus, MIS could po-
tentially act directly on normal or abnormal breast tissue to stim-
ulate carcinogenesis. Although at high doses MIS has been shown 
to inhibit mammary tumor growth in vitro and in animal models 
(  6  ,  7  ), its effect on carcinogenesis at physiological concentrations is 
unknown. 
  MIS is a biomarker of ovarian function with properties that may 
make it particularly informative in epidemiological research. 
Although serum concentrations decline with age after 29 years (  3  ), 
women’s relative concentrations track over time such that age-ad-
justed differences from mean concentrations in serum samples 
collected 4 years apart are correlated (  r   = .66;   P   < .01) (  4  ). MIS 
concentrations do not vary markedly by day of the menstrual cycle 
(  14    –    16  ). MIS also is stable between menstrual cycles; the intraclass 
correlation for MIS in serum from three consecutive menstrual 
cycles was .89 (  17  ). In an analysis based on the Columbia, MO 
Serum Bank, we similarly observed an intraclass correlation coefﬁ  -
cient of .87 for MIS levels in serum samples collected from the 
same women at least 1 year apart (  18  ). 
  In women, MIS is produced by ovarian granulosa cells of pre-
antral and small antral follicles (  19  ). Within the ovary, MIS sup-
presses follicle maturation by inhibiting the recruitment of 
primordial follicles into the pool of growing follicles and by de-
creasing the responsiveness of growing follicles to FSH (  19  ). 
Production of estradiol in granulosa cells is critical for follicle 
maturation. MIS has been reported to inhibit FSH-stimulated 
aromatase activity in granulosa cells, resulting in decreased intra-
cellular estradiol levels and suppressed follicle maturation (  20  ). 
However, similar to our study, most investigations do not ﬁ  nd an 
association between total serum estradiol and MIS levels in healthy 
women (  3  ,  16  ,  21    –    23  ). We observed a weak positive correlation 
between serum MIS and non  –  SHBG-bound estradiol that, to our 
knowledge, has not been reported previously and that could be 
related to the older age of the participants and to the inclusion of 
women who were not regularly menstruating. 
  Serum MIS concentration is associated with the number of 
small antral follicles (  3  ,  23  ,  24  ), and serum levels decline with 
ovarian aging, reaching undetectable levels at menopause when the 
pool of follicles is depleted (  3  ,  4  ). This decline in MIS levels begins 
at a young age, many years before the menopausal transition. In 
a longitudinal analysis, serum MIS declined 38% for a period of 
2.6 years in women whose mean age was 29 years at their ﬁ  rst 
measurement (  3  ). However, even though MIS concentrations 
decline with aging, women often maintain the same relative con-
centration for their age over time (  4  ). Thus, premenopausal 
women of the same age with higher MIS levels may experience 
menopause at a later age, which could contribute to increased 
breast cancer risk. However, the odds ratio for breast cancer in-
creases about 4% for each additional year of age at menopause 
(  25  ), which translates into an odds ratio of approximately 1.48 for 
a 10-year difference. In comparison, we observed an odds ratio 
between 7 and 10 for women with elevated MIS levels depending 
on oral contraceptive use. Therefore, later age at menopause 
would not explain most of the increased risk of breast cancer asso-
ciated with elevated serum MIS levels. 
  MIS was positively related to breast cancer risk among women 
who were diagnosed with breast cancer when younger than 55 
years, but the association was stronger among women diagnosed at 
an older age. MIS is not detectable in serum after menopause (  3  ), 
and its continued association with breast cancer after menopause 
suggests two hypotheses. Exposure to higher MIS levels before 
menopause could permanently alter the breast to increase long-
term risk of developing breast cancer. Alternatively, serum MIS 
could be a marker of underlying differences in ovarian physiology 
that encompass multiple endocrine and/or metabolic alterations, 
some of which may persist after menopause. MIS levels are ele-
vated in women with polycystic ovarian disease (  21  ,  23  ), but speciﬁ  c 
MIS-related hormonal alterations that could lead to an increased 
risk of breast cancer have yet to be clariﬁ  ed. 
  Some data indicate that the ovaries continue to produce testos-
terone after menopause (  26  ,  27  ). MIS concentration was previously 
reported to be positively associated with testosterone in healthy 
women (  22  ), but results are not consistent across studies (  23  ). In 
our analysis, MIS and testosterone were positively correlated, but 
adjustment for total and non  –  SHBG-bound testosterone did not 
substantially alter associations of MIS with breast cancer in women 
not using oral contraceptives. Thus, although serum testosterone 
is related to breast cancer risk in postmenopausal women (  28  ), it is 
unlikely to be the sole explanation for the continued strong associ-
ation of MIS with breast cancer long after MIS is undetectable in 
serum, and other hormones and growth factors could also be 
involved. 
  Our study had many strengths. Most notably, MIS was mea-
sured in serum that was collected many years before the case 
patients  ’   breast cancer diagnoses, cohort follow-up was 91% 
  Table 6    .       Relative odds ratios (ORs) and confidence intervals (CIs) of breast cancer by serum Müllerian inhibiting substance (MIS) 
concentration stratified by age at diagnosis   
    MIS, ng/mL
Age <55 y at diagnosis  *  Age   ≥  55 y at diagnosis  *   
  No. of case patients/
No. of control subjects OR (95% CI)   P    † 
No. of case patients/
No. of control subjects OR (95% CI)   P      †       
       .03     <.001 
  <0.06 6/16 1.0  22/74 1.0  
  0.1  –  0.5 5/19 1.2 (0.3 to 5.4)   27/36 5.7 (2.1 to 15.5)  
  0.6  –  8.0 21/26 3.9 (0.9 to 16.3)   24/33 9.6 (2.8 to 33.3)    
    *     Case patients and control subjects are from the prospective case  –  control study of serum MIS and breast cancer risk. Case patients and control subjects were 
matched on age, date, hour, and days since last menses at blood collection. MIS cut points define tertiles of MIS estimated from all participants.   
      †         P   values (two-sided) were calculated by using conditional logistic regression with tertile ranks entered as a linear term to test for trend using a Wald test.     1508   Articles | JNCI  Vol. 101, Issue 21  |  November 4, 2009
complete, and the number of breast cancer case patients was large 
enough to draw meaningful conclusions. 
  It also had several potential limitations. These limitations in-
cluded small numbers for some stratiﬁ  ed analyses and lack of data 
on age at menopause. In addition, although the case patients and 
control subjects in this study differed as expected on some charac-
teristics such as family history of breast cancer, the lower frequency 
of oral contraceptive use in case patients compared with control 
subjects is at odds with most data (  29  ). The use of oral contracep-
tives as a whole was lower than expected, and these results could 
reﬂ  ect the underlying distribution in the cohort; alternatively, the 
results could suggest that control subjects in the study are not 
representative of unaffected women in the cohort. If the latter is 
true, the observed associations between serum MIS and breast 
cancer could be biased. The positive association of serum MIS 
with breast cancer risk that we observed is opposite of what would 
be predicted based on the limited in vitro and in vivo results from 
animal studies on the association of MIS with mammary tumori-
genesis (  6  ,  7  ). However, more preclinical data support a protective 
effect of MIS for ovarian cancer (  30  ), and our pilot data that show 
an inverse association of MIS with ovarian cancer risk in this 
cohort are consistent with that (data not shown). Thus, the positive 
association that we observed between serum MIS and breast cancer 
risk, although unexpected based on earlier ﬁ  ndings, could be real. 
  Few cancer risk factors are as strongly associated with breast 
cancer as that we observed (OR = 9.8) for women in the highest vs 
lowest quartile of MIS. However, we previously reported odds 
ratios of 5.2 and 6.2 for breast cancer associated with elevated non  – 
  SHBG-bound estradiol and testosterone in this cohort (  31  ). 
Premenopausal women included in the MIS analysis were distinct 
from those in our previous analysis of hormones and breast cancer 
risk that only included women who were postmenopausal at blood 
collection. However, the very strong association with endogenous 
hormone levels in both groups could reﬂ  ect the same underlying, 
but as yet unidentiﬁ  ed, cause. In the pooled analysis of prospective 
studies on serum hormones and breast cancer, the odds ratios for 
postmenopausal women in the highest quintiles of non  –  SHBG-
bound estradiol and testosterone compared with the lowest were 
2.39 and 2.22, respectively (  28  ). The stronger associations in 
the Columbia, MO Serum Bank, in part, may have been related to 
the limited use of exogenous hormones in this cohort. None of the 
participants in the pooled analysis were using hormone replace-
ment therapy at the time of blood collection, but some had used it 
previously. When these women were excluded, associations of 
endogenous hormones with breast cancer were stronger. Women 
in the cohort who develop breast cancer potentially also could be 
particularly susceptible to hormonal inﬂ  uences on risk. If this is the 
case, risk estimates would be expected to be smaller in other 
cohorts. Nonetheless, our results, if conﬁ  rmed, could suggest that 
underlying differences in ovarian folliculogenesis associated with 
elevated serum MIS contribute to breast cancer risk. 
  In conclusion, MIS may be a biomarker of ovarian function 
that is associated with increased breast cancer risk. Additional 
research is needed, including conﬁ  rmatory epidemiological studies 
on the association of serum MIS with breast cancer and studies 
aimed at identifying the biological mechanism underlying the 
association.   
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